The FXYD proteins (FXYD domain-containing ion transport regulators) are a family of seven distinct proteins that play crucial roles in regulating Na+/K+-ATPase (NKA) activity. Each of these proteins is characterized by a conserved 35-amino-acid FXYD domain, essential for their functions, and exhibits tissue-specific expression, contributing to diverse roles in various tissues.

Research over the years has highlighted the role of the FXYD proteins in regulating numerous physiological processes, including ion transport, neuronal activity, cell adhesion, and migration; conversely, their altered expression has been implicated in the progression of various diseases, such as cancer, neurological, cardiovascular, and renal diseases, and others. Understanding the FXYD proteins and their underlying regulatory mechanisms may therefore aid in identifying novel therapeutic targets.

Developed by a consortium of 30 public and private partners, ACCESS-AD (“Advancing Clinical Care and Equity through Scalable Solutions in Alzheimer’s Disease diagnosis and treatment”) is focused on bringing innovations to routine clinical practice for Alzheimer’s disease, supporting timely diagnosis, treatment and monitoring across diverse healthcare settings. Launching on 13 January 2026, ACCESS-AD is funded for a period of 5 years by the Innovative Health Initiative (IHI), an EU Public-Private Partnership supporting health research and innovation. 

As Australians return to work after the holidays, many will be reflecting on their health and wellbeing goals for the year ahead. New research reveals that while workplace factors like long hours, work-related stress and shift work do influence high-risk drinking, personal and social factors play an even bigger role.